Skip to main content
Erschienen in: Medical Oncology 1/2013

01.03.2013 | Original Paper

Predictors and survival in patients with melanoma brain metastases

verfasst von: Ugo Bottoni, Rita Clerico, Giovanni Paolino, Marina Ambrifi, Paola Corsetti, Stefano Calvieri

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Brain metastases (BM) are one of the most frequent neurological complications of cancers. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10–40 %, and many patients have subclinical BM (>73 %). We computer-searched the clinical records of all our patients registered into a database to identify patients that presented or developed BM. A total of 49 patients with melanoma BM were included in our analysis. General time to brain metastases (TTBM) was 23 months. The nonparametric test between TTBM and the single variables showed an association between TTBM and Breslow thickness (p < 0.0076; Spearman’s coefficient—0.411), ulceration (p = 0.0656; Spearman’s coefficient—0.287) and positive sentinel lymph node (p < 0.0015; Spearman’s coefficient—0.475). Performing multiple regression, positive SLN remained the only, statistically significant, predictive variable (p < 0.01). Regarding the first melanoma site, the axial sites were more likely to develop BM than peripheral ones (p < 0.001). The analysis of brain metastasis survival (BMS) with Kaplan–Meier curves has resulted in a median survival rate of 6 months (range 1–134 months) and was strongly related to response to treatment, number of parenchymal lesions, presence or absence of symptoms. The results of the current analysis revealed clinical and primary tumor characteristics associated with the development of BM, TTBM, and BMS. The SNL was found to be the strongest predictor for BM development.
Literatur
1.
Zurück zum Zitat Nayak L, Quant Lee E, Wen PY. Epidemiology of brain metastases. Cur Oncol Rep. 2012;14:48–54.CrossRef Nayak L, Quant Lee E, Wen PY. Epidemiology of brain metastases. Cur Oncol Rep. 2012;14:48–54.CrossRef
2.
Zurück zum Zitat De Angelis LM, Posner JB. Neurologic complications of cancer. New York: Oxford University Press; 2009. De Angelis LM, Posner JB. Neurologic complications of cancer. New York: Oxford University Press; 2009.
3.
Zurück zum Zitat Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973–2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–72.PubMedCrossRef Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973–2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–72.PubMedCrossRef
4.
Zurück zum Zitat Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res. 2011;30:10.PubMedCrossRef Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res. 2011;30:10.PubMedCrossRef
5.
Zurück zum Zitat Counsell CE, Collie DA, Grant R. Incidence of intracranial tumors in the Lothian region of Scotland, 1989–1990. J Neurol Neurosurg Psychiatry. 1996;61:143–50.PubMedCrossRef Counsell CE, Collie DA, Grant R. Incidence of intracranial tumors in the Lothian region of Scotland, 1989–1990. J Neurol Neurosurg Psychiatry. 1996;61:143–50.PubMedCrossRef
6.
Zurück zum Zitat Flanigan JC, Jilaveanu LB, Faries M, Sznol M, Ariyan S, Yu JB, et al. Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer. 2011;35:200–10.PubMedCrossRef Flanigan JC, Jilaveanu LB, Faries M, Sznol M, Ariyan S, Yu JB, et al. Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer. 2011;35:200–10.PubMedCrossRef
7.
Zurück zum Zitat Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807–10.PubMedCrossRef Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807–10.PubMedCrossRef
8.
Zurück zum Zitat de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43:3427–33.PubMed de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43:3427–33.PubMed
9.
Zurück zum Zitat Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11–20.PubMedCrossRef Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11–20.PubMedCrossRef
10.
Zurück zum Zitat Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117:1711–20.PubMedCrossRef Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117:1711–20.PubMedCrossRef
11.
12.
Zurück zum Zitat Meier S, Baumer BG, Maier T, Wellis G, Burg G, Seifert B, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie. 2004;27:145–9.PubMedCrossRef Meier S, Baumer BG, Maier T, Wellis G, Burg G, Seifert B, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie. 2004;27:145–9.PubMedCrossRef
13.
Zurück zum Zitat Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeigeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuros Oncol. 2008;10:199–207.CrossRef Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeigeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuros Oncol. 2008;10:199–207.CrossRef
14.
Zurück zum Zitat Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0–4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Onco 2000;l7:87–7. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0–4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Onco 2000;l7:87–7.
15.
Zurück zum Zitat Eigenther TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, et al. Number of metastases, serum lactate deydrogenase level, and type of treatment and prognostic factors in patients with brain metasatses of malignant melanoma. Cancer. 2011;117:1697–703.CrossRef Eigenther TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, et al. Number of metastases, serum lactate deydrogenase level, and type of treatment and prognostic factors in patients with brain metasatses of malignant melanoma. Cancer. 2011;117:1697–703.CrossRef
16.
Zurück zum Zitat Grob JJ, Regis J, Laurans R, Delaunay M, Wolkenstein P, Paul K, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de cancerologie Cutanee. Eur J Cancer. 1998;10:1187–92.CrossRef Grob JJ, Regis J, Laurans R, Delaunay M, Wolkenstein P, Paul K, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de cancerologie Cutanee. Eur J Cancer. 1998;10:1187–92.CrossRef
17.
Zurück zum Zitat Raizer JJ, Hwu WJ, Pangeas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomenigeal metastases from cutanous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199–207.PubMedCrossRef Raizer JJ, Hwu WJ, Pangeas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomenigeal metastases from cutanous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199–207.PubMedCrossRef
18.
Zurück zum Zitat Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117:1687–96.PubMedCrossRef Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117:1687–96.PubMedCrossRef
19.
Zurück zum Zitat Retsas S, Gershuny AR. Central nervous system involvement in malignant melanoma. Cancer. 1988;61:1926–34.PubMedCrossRef Retsas S, Gershuny AR. Central nervous system involvement in malignant melanoma. Cancer. 1988;61:1926–34.PubMedCrossRef
20.
Zurück zum Zitat Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer. 2010;102:1213–8.PubMedCrossRef Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer. 2010;102:1213–8.PubMedCrossRef
21.
Zurück zum Zitat Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer. 2007;109:306–12.PubMedCrossRef Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer. 2007;109:306–12.PubMedCrossRef
22.
Zurück zum Zitat Schild SE, Behl D, Markovic SN, Brown PD, Sande JR, Deming RL, et al. Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? Am J Clin Oncol. 2010;33:633–6.PubMedCrossRef Schild SE, Behl D, Markovic SN, Brown PD, Sande JR, Deming RL, et al. Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? Am J Clin Oncol. 2010;33:633–6.PubMedCrossRef
23.
Zurück zum Zitat Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293.PubMedCrossRef Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293.PubMedCrossRef
24.
Zurück zum Zitat Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by Radiation Therapy Oncology Group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer. 2002;94:2265–72.PubMedCrossRef Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by Radiation Therapy Oncology Group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer. 2002;94:2265–72.PubMedCrossRef
25.
Zurück zum Zitat Harrison BE, Johnson JL, Clough RW, Halperin EC. Selection of patients with melanoma brain metastases for aggressive treatment. Am J Clin Oncol. 2003;26:354–7.PubMed Harrison BE, Johnson JL, Clough RW, Halperin EC. Selection of patients with melanoma brain metastases for aggressive treatment. Am J Clin Oncol. 2003;26:354–7.PubMed
26.
Zurück zum Zitat Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer. 1984;53:2550–2.PubMedCrossRef Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer. 1984;53:2550–2.PubMedCrossRef
27.
Zurück zum Zitat Le Scodan R, Jouanneau L, Massard C, Gutierrez M, Kirova Y, Cherel P, et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. Cancer. 2011;11:395.PubMed Le Scodan R, Jouanneau L, Massard C, Gutierrez M, Kirova Y, Cherel P, et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. Cancer. 2011;11:395.PubMed
28.
Zurück zum Zitat Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg. 2002;96:552.PubMedCrossRef Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg. 2002;96:552.PubMedCrossRef
29.
Zurück zum Zitat Kaye AH, Lawws ER Jr. Brain tumors. An encyclopedic approach. New York: Churchill Livingstone; 1995. Kaye AH, Lawws ER Jr. Brain tumors. An encyclopedic approach. New York: Churchill Livingstone; 1995.
30.
Zurück zum Zitat Ewend MG, Carey LA, Brem H. Treatment of melanoma metastases in the brain. Semin Surg Oncol. 1996;12:429.PubMedCrossRef Ewend MG, Carey LA, Brem H. Treatment of melanoma metastases in the brain. Semin Surg Oncol. 1996;12:429.PubMedCrossRef
31.
Zurück zum Zitat Wronski M, Arbit E. Surgical treatment of brain metatsases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9–18.PubMedCrossRef Wronski M, Arbit E. Surgical treatment of brain metatsases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9–18.PubMedCrossRef
32.
Zurück zum Zitat Goldlust SA, Hsu M, Lassman AB, Panageas KS, Avila EK. Seizure prophylaxis and melanoma brain metastases. J Neuroncol. 2012;108:109–14.CrossRef Goldlust SA, Hsu M, Lassman AB, Panageas KS, Avila EK. Seizure prophylaxis and melanoma brain metastases. J Neuroncol. 2012;108:109–14.CrossRef
33.
Zurück zum Zitat Goulart RC, Mattei TA, Ramina R. Cerebral melanoma metastases: a critical review on diagnosis methods and therapeutic options. ISNR Surg 276908 (2011). Goulart RC, Mattei TA, Ramina R. Cerebral melanoma metastases: a critical review on diagnosis methods and therapeutic options. ISNR Surg 276908 (2011).
34.
Zurück zum Zitat Bottoni U, Bonaccorsi P, Devirgiliis V, Panasiti V, Borroni RG, Trasimeni G, et al. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Jpn J Clin Oncol. 2005;35:507–13.PubMedCrossRef Bottoni U, Bonaccorsi P, Devirgiliis V, Panasiti V, Borroni RG, Trasimeni G, et al. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Jpn J Clin Oncol. 2005;35:507–13.PubMedCrossRef
Metadaten
Titel
Predictors and survival in patients with melanoma brain metastases
verfasst von
Ugo Bottoni
Rita Clerico
Giovanni Paolino
Marina Ambrifi
Paola Corsetti
Stefano Calvieri
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0466-2

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.